|
Combination Osteogenic Therapy in Established Osteoporosis Clinical Trials Info presented on Clinical Trials Search isn't intended to be a substitute for certified health advice, travels to or treatment by using a genuine physician. We are not physicians. Always consult your dr. on Combination Osteogenic Therapy in Established Osteoporosis conditions. Clinical Trials Search.org is a site committed to listing clinical research studies in human subjects. Combination Osteogenic Therapy in Established Osteoporosis Clinical research trials and Combination Osteogenic Therapy in Established Osteoporosis health trials occur in hundreds of cities throughout the U.S.A.. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials typically assess the effectivity of new drugs. The propose of the studies / undertakings is to resolve certain human health questions. Clinical trials are a popular means for physicians, government agencies, and private sector companies to locate treatments for all sorts of conditions, including Combination Osteogenic Therapy in Established Osteoporosis. Combination Osteogenic Therapy in Established Osteoporosis Clinical Trials and other clinical trials permit volunteers to acquire medical treatment choices before they are available to the masses. Some times the test subjects obtain professional assistance for free, and every now and again they are compensated for their time. Sometimes there is a cost for a Combination Osteogenic Therapy in Established Osteoporosis clinical trial. Participants oftentimes recieve the most expert healthcare available for their Combination Osteogenic Therapy in Established Osteoporosis condition. Hazards are a reality, however, and can include extra or frequent physician visits, health risks (potentially life-endangering), and/or the treatment being uneffective. Trials are federally governed with rigorous guidelines to protect clinical trials subjects.
|
|
|
|
|
|
|
Home > "C" Clinical Trials Conditions > Combination Osteogenic Therapy in Established Osteoporosis  Combination Osteogenic Therapy in Established Osteoporosis
Combination Osteogenic Therapy in Established Osteoporosis
For Condition: Osteoporosis, Post-Menopausal
Status: Recruiting
Sponsor(s): Department of Veterans Affairs Medical Research Service ,
Synopsis: This study is designed to determine if combining parathyroid (PTH 1-34) with fluoride (MFPSR) therapy in a cyclic treatment regimen will: (1) produce a greater increase in bone density of the spine than would be produced by either treatment alone; (2) prevent the resistance (i.e., decreased bone formation and no further increase in bone density) that is observed within 18-24 months of PTH therapy; (3) eliminate the calcium deficiency and osteomalacia that can occur with fluoride; (4) prevent excessive bone fluoride content; and (5) result in an increase in bone density which is maintained after treatment is discontinued.
Details: This is a 3-yr, single center, open label, active controlled, randomized study of approximately 99 postmenopausal females with osteoporosis of spine or femoral neck. Patients will be assigned to 1 of 3 groups: 1) PTH 1-34; 2) Fluoride; 3) PTH and fluoride. The treatment period is 3 years with 3-month cycles of therapy. PTH will be administered subcutaneously by injection 600 units daily for 28 days the first month of each 3-month cycle. Fluoride will be administered orally one 76mg tablet twice daily (providing 20 mg fluoride/day), during the last 2 months of each cycle. Calcium will be provided 800mg/day during month 1 and 1500-2000mg for months 2 and 3 of each cycle.
Eligibility:
Study Type: Interventional, Treatment, Randomized, Open Label
Minimum Age/Maximum Age: 60 Years/80 Years
Genders: Female
Protocol Entry Criteria: Female, aged 60-80, postmenopausal greater than or equal to 5 years, BMD -2.5 to -4.0 at lumbar spine or femoral neck and one standard deviation below young adult mean in the other site, or -2.0 with fracture. Vertebral fracture 0-1. Exclusion: more than 1 vertebral fracture in lumbar spine or more than 4 fracture in the T-L spine. Weight less than 45 kg or more than 80 kg, or more than 25% above ideal body weight. Present cardiac disease present. Diseases or conditions known to affect bone metabolism. Therapies with drugs that affect bone metabolism within 6 months. Fluoride or Biophosphonates at any time.
Total Enrollment:
Location and Contact Information:
Jerry L. Pettis Memorial Veterans Medical Center *Recruiting*
Loma Linda, California, 92357
United States
Recruiting Cesar Libanati 909-558-3101
Additional Information:
Study ID Numbers: ENDO-022-98S;
Study Start Date: November 1998
Record last reviewed: June 2001
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00018447
Other Osteoporosis, Post-Menopausal Studies:
1. Combination Osteogenic Therapy in Established Osteoporosis
Related Studies:
Other Osteoporosis, Post-Menopausal Clinical Trials
Other California Clinical Trials
Other Loma Linda Clinical Trials
Combination Osteogenic Therapy in Established Osteoporosis
|
|
|
|
|
|
|
|
